Monitor IM8's customer growth and retention metrics in upcoming earnings; watch for updates on Superpower integration efficacy and whether the partnership drives measurable increases in IM8 subscription uptake or renewal rates. The claimed $100M+ annualized recurring revenue should be verified in future financial disclosures.
Price Chart
Executive Summary
Prenetics (PRE) announced a strategic partnership between its IM8 supplement brand and Superpower, a preventive health platform, to integrate clinical-grade supplementation with comprehensive blood testing. IM8 customers gain access to discounted Superpower blood testing memberships, while Superpower will feature IM8's Daily Ultimate Essentials as a recommended supplement in its personalized health protocols. This creates a closed-loop system allowing consumers to measure the impact of supplements using biomarker data.
Key Facts
- IM8 90-day subscribers can access Superpower's annual blood testing membership for $49 (75% off standard $199 price).
- Monthly IM8 subscribers get Superpower membership for $99 (50% off).
- Superpower offers testing across 100+ biomarkers via 2,000+ Quest Diagnostics locations or at-home draw.
- IM8's Daily Ultimate Essentials will be integrated into Superpower's supplement marketplace and personalized health protocols.
- Prenetics claims IM8 has surpassed $100 million in annualized recurring revenue within 11 months of launch.
- The partnership aims to close the loop between supplement use and measurable health outcomes using biomarker data.
Financial Impact
Potential incremental revenue from expanded customer acquisition and cross-selling; $100M+ annualized recurring revenue claimed for IM8
Risk Factors
- The $100M+ annualized recurring revenue figure is unaudited and not confirmed in a regulatory filing.
- Partnership success depends on consumer adoption and actual behavior change, which may not materialize.
- Revenue impact may be delayed or diluted if integration challenges arise or customer engagement remains low.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261483 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $21.27 | awaiting T+60 | — | $18.37 (−13.63%) |
Sep 22, 2026 4w ago | F-1/A | $22.90 | awaiting T+60 | — | $18.37 (−19.78%) |
Aug 26, 2026 8w ago | 6-K | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 26, 2026 8w ago | Insider Cluster | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 26, 2026 8w ago | 3 | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 20, 2026 9w ago | 6-K | $17.97 | awaiting T+60 | — | $18.37 (+2.23%) |
Aug 18, 2026 9w ago | 6-K | $19.40 | awaiting T+60 | — | $18.37 (−5.31%) |
Aug 18, 2026 9w ago | Press Release | $19.40 | awaiting T+60 | — | $18.37 (−5.31%) |
Aug 17, 2026 10w ago | 6-K | $19.37 | awaiting T+60 | — | $18.37 (−5.16%) |
Aug 7, 2026 11w ago | F-1/A | $18.26 | awaiting T+60 | — | $18.37 (+0.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers